Tumor immunotherapy is only effective in a fraction of patients due to a low response rate
and severe side effects, and these challenges of immunotherapy in clinics can be addressed …

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

The use of probiotics by cancer patients is increasing, including among those undergoing
immune checkpoint inhibitor (ICI) treatment. Here, we elucidate a critical microbial-host …

The accumulation of senescent cells is a major cause of age-related inflammation and
predisposes to a variety of age-related diseases. However, little is known about the …

Radiotherapy (RT) is delivered for purposes of local control, but can also exert systemic
effect on remote and non-irradiated tumor deposits, which is called abscopal effect. The view …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

Background Dostarlimab is a humanized monoclonal antibody that binds with high affinity to
PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. We report interim data from …

Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …

CD8+ T cell-mediated cancer clearance is often suppressed by the interaction between
inhibitory molecules like PD-1 and PD-L1, an interaction acts like brakes to prevent T cell …

Immunometabolic intervention has been applied to treat cancer via inhibition of certain
enzymes associated with intratumoral metabolism. However, small-molecule inhibitors and …